Y-Intercept (HK)’s Arcus Biosciences RCUS Stock Holding History

Y-Intercept (HK)’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-86,192	Closed	-$1.86M	–	2083
2026 Q1	$1.86M	Buy	+86,192	New	+$1.86M	0.04%	747
2025 Q3	–	Sell	-16,794	Closed	-$137K	–	1953
2025 Q2	$137K	Sell	16,794 -14,620	-47%	-$125K	﹤0.01%	1509
2025 Q1	$247K	Buy	+31,414	New	+$364K	0.02%	969
2024 Q4	–	Sell	-23,581	Closed	-$361K	–	1572
2024 Q3	$361K	Buy	23,581 +11,827	+101%	+$186K	0.02%	933
2024 Q2	$179K	Buy	+11,754	New	+$190K	0.01%	1195
2023 Q1	–	Sell	-18,406	Closed	-$381K	–	1470
2022 Q4	$381K	Buy	+18,406	New	+$506K	0.06%	544

Other funds holding RCUS

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

SAM

Seelaus Asset Management Chatham, New Jersey $142M AUM 48.54% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

Y-Intercept (HK)'s RCUS Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 86,192 shares — an estimated $1.86M sold.

Y-Intercept (HK) first reported a position in RCUS in Q4 2022 and held it in 6 quarters. The position peaked at $1.86M in Q1 2026. 23 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Y-Intercept (HK) reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 86,192 Arcus Biosciences shares in Q2 2026, an estimated $1.86M.
Y-Intercept (HK) first reported a position in Arcus Biosciences in Q4 2022 and held it in 6 quarters.
Y-Intercept (HK)'s Arcus Biosciences position peaked at $1.86M in Q1 2026.
23 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.